tetano
Editor, Senior Moderator
Elife
. 2021 Nov 23;10:e70330.
doi: 10.7554/eLife.70330.
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Marloes Grobben[SUP] #[/SUP][SUP] 1 [/SUP], Karlijn van der Straten[SUP] #[/SUP][SUP] 1 [/SUP], Philip Jm Brouwer[SUP] 1 [/SUP], Mitch Brinkkemper[SUP] 1 [/SUP], Pauline Maisonnasse[SUP] 2 [/SUP], Nathalie Dereuddre-Bosquet[SUP] 2 [/SUP], Brent Appelman[SUP] 1 [/SUP], Ah Ayesha Lavell[SUP] 1 [/SUP], Lonneke A van Vught[SUP] 3 [/SUP], Judith A Burger[SUP] 1 [/SUP], Meliawati Poniman[SUP] 1 [/SUP], Melissa Oomen[SUP] 1 [/SUP], Dirk Eggink[SUP] 4 [/SUP], Tom Pl Bijl[SUP] 1 [/SUP], Hugo Dg van Willigen[SUP] 1 [/SUP], Elke Wynberg[SUP] 5 [/SUP], Bas J Verkaik[SUP] 1 [/SUP], Orlane Ja Figaroa[SUP] 1 [/SUP], Peter J de Vries[SUP] 6 [/SUP], Tessel M Boertien[SUP] 6 [/SUP], Amsterdam UMC COVID-19 S3/HCW study group; Marije K Bomers[SUP] 1 [/SUP], Jonne J Sikkens[SUP] 1 [/SUP], Roger Le Grand[SUP] 7 [/SUP], Menno D de Jong[SUP] 8 [/SUP], Maria Prins[SUP] 2 [/SUP], Amy W Chung[SUP] 9 [/SUP], Godelieve J de Bree[SUP] 1 [/SUP], Rogier W Sanders[SUP] 1 [/SUP], Marit J van Gils[SUP] 1 [/SUP]
Affiliations
Abstract
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.
Keywords: COVID-19; SARS-CoV-2; antibodies; coronavirus; cross-reactivity; human; immunology; infectious disease; inflammation; microbiology; vaccine.
. 2021 Nov 23;10:e70330.
doi: 10.7554/eLife.70330.
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Marloes Grobben[SUP] #[/SUP][SUP] 1 [/SUP], Karlijn van der Straten[SUP] #[/SUP][SUP] 1 [/SUP], Philip Jm Brouwer[SUP] 1 [/SUP], Mitch Brinkkemper[SUP] 1 [/SUP], Pauline Maisonnasse[SUP] 2 [/SUP], Nathalie Dereuddre-Bosquet[SUP] 2 [/SUP], Brent Appelman[SUP] 1 [/SUP], Ah Ayesha Lavell[SUP] 1 [/SUP], Lonneke A van Vught[SUP] 3 [/SUP], Judith A Burger[SUP] 1 [/SUP], Meliawati Poniman[SUP] 1 [/SUP], Melissa Oomen[SUP] 1 [/SUP], Dirk Eggink[SUP] 4 [/SUP], Tom Pl Bijl[SUP] 1 [/SUP], Hugo Dg van Willigen[SUP] 1 [/SUP], Elke Wynberg[SUP] 5 [/SUP], Bas J Verkaik[SUP] 1 [/SUP], Orlane Ja Figaroa[SUP] 1 [/SUP], Peter J de Vries[SUP] 6 [/SUP], Tessel M Boertien[SUP] 6 [/SUP], Amsterdam UMC COVID-19 S3/HCW study group; Marije K Bomers[SUP] 1 [/SUP], Jonne J Sikkens[SUP] 1 [/SUP], Roger Le Grand[SUP] 7 [/SUP], Menno D de Jong[SUP] 8 [/SUP], Maria Prins[SUP] 2 [/SUP], Amy W Chung[SUP] 9 [/SUP], Godelieve J de Bree[SUP] 1 [/SUP], Rogier W Sanders[SUP] 1 [/SUP], Marit J van Gils[SUP] 1 [/SUP]
Affiliations
- PMID: 34812143
- DOI: 10.7554/eLife.70330
Abstract
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.
Keywords: COVID-19; SARS-CoV-2; antibodies; coronavirus; cross-reactivity; human; immunology; infectious disease; inflammation; microbiology; vaccine.